Blastoma

(L to R) Co-first and co-corresponding author Min Pan, Ph.D., co-first author Yinwen Zhang, Ph.D., St. Jude Department of Computational Biology, co-corresponding author John Easton, Ph.D., St. Jude Computational Biology Genomics Laboratory director and senior co-corresponding author Paul Geeleher, Ph.D., St. Jude Department of Computational Biology. Credit: St. Jude Children's…

Proceedings of the National Academy of Sciences, Volume 122, Issue 9, March 2025. SignificanceThe distinctive nature of glioblastoma (GBM) and the blood–brain barrier (BBB) are obstacles for therapies that aim to permanently stop glioma cells from dividing. Similar to reprogramming normal cells, “differentiation therapies” try to push ...Read More

Oncology/Hematology > Other Cancers — Represents the longest reported survival after CAR-T for an active malignancy by Mike Bassett, Staff Writer, MedPage Today February 19, 2025 A neuroblastoma patient treated with CAR T-cell therapy as a child achieved a complete response and remains in remission more than 18 years later.…

A microscopic image of a neuroblastoma tumour Simon Belcher/Alamy A cancer therapy that uses genetically engineered immune cells, called CAR T-cells, has kept a person free of a potentially fatal nerve tumour for a record-breaking 18 years. “This is, to my knowledge, the longest-lasting complete remission in a patient who…

“The first thing that went through my mind was this must be a mistake. It didn’t seem real.” Those were Michael Strahan’s words after he found out that his daughter, Isabella Strahan, had medulloblastoma—a malignant brain tumor. After undergoing a number of surgeries and multiple rounds of chemo and radiation therapy,…

The role of glioma-associated myeloid cells in tumor growth and immune evasion remains poorly understood. We performed single-cell RNA sequencing of immune and tumor cells from 33 gliomas, identifying two distinct myeloid-derived suppressor cell (MDSC) ...Read More

A recent clinical trial took a different approach to treating glioblastoma, with signs of extended survival. (Image credit: DR P. MARAZZI/SCIENCE PHOTO LIBRARY via Getty Images) A new therapy for the most aggressive type of brain cancer can extend patients' survival while cutting the length of treatment. The cancer, glioblastoma…

A study co-led by UCLA scientists has found targeting a protein called endocan and its related signaling pathway could be a promising new approach for treating glioblastoma, an aggressive and lethal type of brain cancer. The team of researchers discovered that endocan, which is produced by endothelial cells lining blood…

Please complete security verification This request seems a bit unusual, so we need to confirm that you're human. Please press and hold the button until it turns completely green. Thank you for your cooperation! Press and hold the button If you believe this is an error, please contact our support…

Proceedings of the National Academy of Sciences, Volume 121, Issue 52, December 2024. SignificanceSonic hedgehog (SHH) promotes proliferation of granule cell (GC) progenitors in the postnatal cerebellum and in the pediatric tumor, medulloblastoma, through specialized compartments called primary cilia. During neuronal maturation, GCs stop ...Read More